Top Abbott Executive Makes Significant Stock Sale!

New insider activity at Abbott Laboratories ( (ABT) ) has taken place on August 11, 2025.

Philip P Boudreau, the Executive Vice President and Chief Financial Officer of Abbott Laboratories, has recently sold 5,550 shares of the company’s stock, amounting to a total transaction value of $746,752.

Recent Updates on ABT stock

Abbott Laboratories has seen notable developments in its stock performance and analyst evaluations. Despite an underwhelming Q2 report, Jefferies upgraded Abbott to a Buy, citing the recent share selloff as overly punitive and highlighting the company’s potential for accelerated growth in 2026. The company’s Q2 earnings report showed a 7.4% increase in reported sales and a 6.9% increase in organic sales, with significant growth in the Medical Devices segment. However, challenges persist in the Diagnostics segment due to reduced COVID-19 testing sales and market issues in China. Abbott’s strategic initiatives, including FDA approval for new products and plans for a new manufacturing facility, underscore its commitment to innovation. Looking forward, Abbott projects continued organic sales growth and an optimistic outlook for 2026, driven by product pipeline advancements and market expansion.

Spark’s Take on ABT Stock

According to Spark, TipRanks’ AI Analyst, ABT is a Outperform.

Abbott Laboratories’ strong financial performance and robust earnings call highlights, particularly in Medical Devices, contribute significantly to its overall score. While technical indicators are neutral, and valuation is reasonable, the company faces challenges in the Diagnostics segment and from tariffs. However, its strategic initiatives and market resilience support a positive outlook.

To see Spark’s full report on ABT stock, click here.

More about Abbott Laboratories

YTD Price Performance: 20.43%

Average Trading Volume: 6,623,517

Technical Sentiment Signal: Buy

Current Market Cap: $233.7B